Sentreheart

Sentreheart is a medical device company that specializes in developing percutaneous technologies for the closure of the left atrial appendage (LAA). Its primary product, the LARIAT Suture Delivery Device, uses a unique epicardial approach to ligate the LAA with a pre-tied suture, avoiding the need for permanent metal implants. The company's technology is designed to reduce the risk of stroke in patients with atrial fibrillation by excluding the LAA, which is a common source of blood clots. In 2019, Sentreheart was acquired by AtriCure, a leader in surgical treatments for atrial fibrillation, for an upfront payment of $40 million and potential milestones. The acquisition integrated Sentreheart's LARIAT system and the pivotal aMAZE clinical trial into AtriCure's portfolio.